Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Lamotrigine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A known ✓ | Q15858 | 11/20 | 0.91 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.91 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.91 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.91 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.91 |
| ▸ | SCN10A known ✓ | Q9Y5Y9 | 1/20 | 0.91 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.91 |
| ▸ | MAOA | P21397 | 1/20 | 0.91 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.91 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.91 |
| ▸ | BLM | P54132 | 1/20 | 0.91 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.91 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.91 |
| ▸ | PTPN11 | Q06124 | 6/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lamotrigine SCHEMBL29801510 | 0.95 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL35439 | 0.95 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL29360953 | 0.95 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL722975 | 0.95 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL17372723 | 0.94 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL1401495 | 0.94 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3167376 | 0.94 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3976546 | 0.94 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL4142403 | 0.94 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3977736 | 0.93 | SCN9A (0.83) | SCN9ACYP2D6MAOAMAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207280-A1 | LAMOTRIGINE HYDRATE CRYSTAL FORM, PREPARATION METHOD THEREFOR, AND COMPOSITION CONTAINING SAME | SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| CN-116942606-A | Preparation method of lamotrigine suspension and dry suspension | 上海奥科达医药科技股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11447456-B1 | Crystalline form of lamotrigine hydrate, method for preparing the same and composition comprising the same | SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (CN) | 2022-09-20 | — | — | US | disclosed |
| CN-114948868-A | Crystal form of lamotrigine hydrate, preparation method thereof and composition containing crystal form | 上海奥科达生物医药科技有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-113214177-B | Crystal form of lamotrigine hydrate, preparation method thereof and composition containing crystal form | 上海奥科达生物医药科技有限公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-113214177-A | Crystal form of lamotrigine hydrate, preparation method thereof and composition containing crystal form | 上海奥科达生物医药科技有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-110078679-B | Lamotrigine pharmaceutical co-crystal and preparation method and application thereof | 广西民族大学 | 2021-04-09 | — | — | CN | disclosed |
| CN-110407762-A | A kind of lamotrigine pharmaceutical co-crystal and preparation method thereof | UNIV GUANGXI NATIONALITIES | 2019-11-05 | — | — | CN | disclosed |
| CN-110078679-A | A kind of lamotrigine pharmaceutical co-crystal and its preparation method and application | 广西民族大学 | 2019-08-02 | — | — | CN | disclosed |
| CN-103360331-B | Novel lamotrigine pharmaceutical co-crystal and preparation method thereof | UNIV TIANJIN | 2015-04-15 | — | — | CN | disclosed |
| CN-103360331-A | Novel lamotrigine pharmaceutical co-crystal and preparation method thereof | UNIV TIANJIN | 2013-10-23 | — | — | CN | disclosed |
| US-8486927-B2 | Crystalline forms of lamotrigine | THAR PHARMACEUTICALS (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120142919-A1 | METHOD FOR SYNTHESIZING LAMOTRIGINE | MEDICHEM, S.A. (ES) | 2012-06-07 | — | — | US | disclosed |
| EP-2128145-A2 | Improved method for synthesizing lamotrigine | Medichem, S.A. (ES) | 2009-12-02 | — | — | EP | disclosed |
| US-20090176787-A1 | Crystalline Forms of lamotrigine | THAR PHARMACEUTICALS (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2009061513-A1 | CRYSTALLINE FORMS OF LAMOTRIGINE | THAR PHARMACEUTICALS (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-2057130-A2 | IMPROVED METHOD FOR SYNTHESIZING LAMOTRIGINE | Medichem, S.A. (ES) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008068619-A2 | IMPROVED METHOD FOR SYNTHESIZING LAMOTRIGINE | MEDICHEM, S.A. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176787-A1 | Crystalline Forms of lamotrigine | SLC6A1, SLC16A1, SLC16A3 | SCN9A 410/4885SCN4A 227/4885SCN5A 98/4885 |
| US-20120142919-A1 | METHOD FOR SYNTHESIZING LAMOTRIGINE | KCNA5, KCNQ5, KCNJ5 | SCN9A 763/4885SCN4A 444/4885SCN5A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.